2026-07-07 · 💊 FDA / Trial
Why is TVRD stock up today?
Tvardi Therapeutics, Inc. Common Stock · TVRD · updated 2026-07-07
PRICE$3.10
CHANGE+54.2%
VOLUME70.9M
6-DAY
In plain English
The only news (“Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline O…”) is stale (148d old) — too old to explain today's move. Likely momentum, not news.
What it means for you
Finished the day strong — the kind of move that sometimes keeps going the next day. Risk level: elevated.
Source: GlobeNewswire Inc.: Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight (2026-02-09)
About Tvardi Therapeutics, Inc. Common Stock
Market cap$29.1M
ExchangeXNAS
Employees12
HQSUGAR LAND, TX
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently
Get moves like this before the bell
Free daily email — the biggest movers, explained. No spam.
Not financial advice. Educational only. AI-assisted summary — verify against the linked source. Data may be delayed.